Alyeska Investment Group L.P. Sells 193,451 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Alyeska Investment Group L.P. lowered its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 62.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 114,707 shares of the company's stock after selling 193,451 shares during the period. Alyeska Investment Group L.P. owned approximately 0.12% of NewAmsterdam Pharma worth $2,948,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of NAMS. Bain Capital Life Sciences Investors LLC boosted its stake in NewAmsterdam Pharma by 2.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company's stock worth $275,481,000 after acquiring an additional 245,197 shares during the last quarter. RA Capital Management L.P. grew its holdings in shares of NewAmsterdam Pharma by 9.7% in the 4th quarter. RA Capital Management L.P. now owns 8,845,000 shares of the company's stock valued at $227,316,000 after buying an additional 781,000 shares during the period. Jennison Associates LLC grew its holdings in shares of NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after buying an additional 2,978,263 shares during the period. Wellington Management Group LLP increased its position in shares of NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after buying an additional 2,222,900 shares in the last quarter. Finally, Capital International Investors acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth $53,007,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Trading Down 4.7 %

Shares of NASDAQ NAMS traded down $0.90 during mid-day trading on Friday, hitting $18.37. The company had a trading volume of 974,266 shares, compared to its average volume of 620,020. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29. The company has a market capitalization of $2.02 billion, a PE ratio of -7.07 and a beta of 0.01. The firm has a 50-day simple moving average of $19.52 and a two-hundred day simple moving average of $21.22.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. Sell-side analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NAMS. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Scotiabank raised their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Needham & Company LLC reduced their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday. Finally, HC Wainwright restated a "buy" rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $43.00.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares of the company's stock, valued at $305,550. The trade was a 90.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James N. Topper bought 4,005 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were acquired at an average price of $21.02 per share, for a total transaction of $84,185.10. Following the transaction, the director now owns 3,012,434 shares in the company, valued at approximately $63,321,362.68. This represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.